Sticker on chest could replace needles for kidney checks in heart failure
NCT ID NCT07349797
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new device that uses a sensor placed on the chest to measure kidney function in 15 adults with heart failure. Participants receive an injection of a fluorescent dye (Relmapirazin) and a standard contrast agent (iohexol), then the sensor tracks how quickly the dye clears from the skin. Researchers compare these readings to traditional blood tests to see if the sensor is accurate enough for routine use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Relmapirazin (Lumitrace) injection and iohexol
What this could lead to
If successful, this could provide a simpler, less invasive way to monitor kidney function in heart failure patients, reducing the need for repeated blood draws.
What could go wrong
This is a very small, early study with only 15 participants, so results may not apply to everyone. The sensor's accuracy may not meet the target, and it is not a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University
New York, New York, 10032, United States
Contact